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Abstract 
Autism is an early-onset developmental disorder with a severe life-long impact on 
behavior and social functioning that has associated metabolic abnormalities. The 
urinary metabolic phenotypes of individuals (age range=3-9 years old) diagnosed 
with autism using the DSM-IV-TR criteria (n=39; male=35; female=4), together 
with their non-autistic siblings (n=28; male=14; female=14) and age-matched 
healthy volunteers (n=34, male=17; female=17) have been characterized for the 
first time using 1H NMR spectroscopy and pattern recognition methods. Novel 
findings associated with alterations in nicotinic acid metabolism within autistic 
individuals showing increased urinary excretion of N-methyl-2-pyridone-5-
carboxamide, N-methyl nicotinic acid and N-methyl nicotinamide, indicate a 
perturbation in tryptophan-nicotinic acid metabolic pathway. Multivariate 
statistical analysis indicated urinary patterns of the free amino acids glutamate 
and taurine were significantly different between groups with the autistic children 
showing higher levels of urinary taurine and a lower level of urinary glutamate 
indicating perturbation in sulfur and amino acid metabolism in these children. 
Additionally, metabolic phenotype (metabotype) differences were observed 
between autistic and control children, which were associated with perturbations 
in the relative patterns of urinary mammalian-microbial co-metabolites including 
dimethylamine, hippurate and phenyacetylglutamine. These biochemical 
changes are consistent with the known abnormalities of gut microbiota found in 
autistic individuals and the associated gastrointestinal dysfunction and may be of 
value in monitoring the success of therapeutic interventions. 
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Introduction 
Autism spectrum disorders (ASD) represent a series of related highly complex 
socio-psychological and neurodevelopmental problems with associated 
metabolic and gastrointestinal abnormalities of poorly-defined etiology. ASD 
typically develop during the first 3 years of life and are characterized by a myriad 
of deficits in language/communication skills, social detachment as well as 
repetitive and stereotypic behaviors.1, 2 The etiopathology of ASD is multi-
factorial and has been linked to genetic abnormalities3, 4 and inborn errors of 
metabolism but there are many postulated, largely ill-defined, triggers including 
infectious agents and environmental toxins.5 Autism has been shown to have 
strong associations with various metabolic abnormalities, immunological function 
and gastrointestinal disturbances, although their mechanistic significance is 
unknown.5-8  
In addition to the panel of neurodevelopmental problems associated with 
ASD, a range of gastrointestinal disorders have been reported and recent studies 
have found that the condition is associated with abnormal gut microbiota.9 There 
is also the possibility of previously unrecognized etiologic connections between 
microbiome disorder and childhood developmental problems, given the 
importance of the microbiome in mammalian metabolism e.g. bile acid 
metabolism.10 Individuals with ASD are commonly exposed to repeated courses 
of multiple antibiotic therapies and this may contribute to the complex 
relationships between gastrointestinal dysbiosis and ASD by altering the 
composition or stability of their microbiota.11-13 Abnormal sulfur metabolism has 
also been shown to typify individuals with ASD.14 Waring et al. showed that 
individuals with autism have lower levels of plasma sulfate, but considerably 
elevated levels of urinary sulfate, as compared to non autistic individuals. These 
data suggest that autistic individuals may have impaired detoxification potential 
involving sulfation, as evidenced by their inability to sulfate the widely used drug 
acetaminophen.14  
The prevalence of autism has increased from 4 in 10 000 children before 
19802, 15 to 99 in 10000 in 2009 in the United Kingdom15 and 53 in 10 000 in 
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2006 in the United States16 alone, but this varies regionally and with ethnicity, 
and also some geographically localized areas have much higher incidences of 
ASD.17 However, it is not clear whether the global increase is due to higher 
prevalence of the disorder, and/or improved early detection/diagnosis. Current 
diagnosis of ASD is subjective and depends on observations of a cluster of 
behaviors and fulfillment of multiple criteria set out in the Diagnostic and 
Statistical Manual of Mental Disorders 4th edition (DSM-IV-TR)18 by a trained 
clinician. At present, there are no reliable biochemical- or genetic-screening tests 
for the disorder and in some cases, particularly in late onset autism, childhood 
development can switch from being normal to showing a delay in acquisition of 
new skills, thus adding to the difficulty for diagnosing ASD. Thus, there is a 
pressing need for new diagnostic tools for ASD that are both sensitive and 
reliable, since early diagnosis can lead to timely interventions and optimized 
clinical management. 
Metabonomic approaches offer the possibility of measuring metabolic end 
points (metabolic profiles) that are determined by genetic and environmental 
factors.19, 20 The application of high throughput metabolic profiling methods using 
high resolution analytical platforms (nuclear magnetic resonance (NMR) 
spectroscopy and/or mass spectrometry (MS)) with subsequent multivariate 
statistical analyses now provides a well-established strategy for differential 
metabolic pathway profiling and disease diagnosis.10, 20-22 Here we apply a 
metabolic profiling approach to capture the global biochemical signature of 
autistic individuals using NMR spectroscopy with multivariate statistical modeling 
to characterize individuals with autism, unaffected siblings and unrelated control 
healthy comparison groups in population-based samples. The key differential 
metabolic features of autism derived from the current study can subsequently be 
evaluated as candidate diagnostic markers in further studies. 
 
Methods 
Sample Collection. The urine samples used in this study were obtained from 
University of South Australia (autistic subjects, their siblings and unrelated 
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healthy subjects; age range: 3-9 years old) and a second group of controls from 
the Swiss Tropical Institute (comparable healthy subjects; age range: 3-9 years 
old), and complied with Australian and Swiss local and national regulations on 
ethics. Each individual and their family gave informed consent for the study to 
take place. The autistic subject group comprised only individuals who had been 
diagnosed as being autistic according to the DSM-IV-TR criteria for diagnosis of 
autism disorder or Asperger sydrome.18 
To address bias deriving from geographical location, urine samples from the 
second group of controls were profiled together with the first group of controls. 
The two control data sets were shown to be statistically indistinguishable (data 
not shown).  
Sample Preparation. Urine samples were prepared by mixing 400 μl of urine 
with 220 μl of a phosphate buffer (90% D2O, 1 mM 3-trimethylsilyl-1-[2,2,3,3-²H4] 
propionate (TSP), and 3 mM sodium azide; pH 7.4) and left to stand for 10 min. 
The samples were centrifuged at 11000 g for 10 min and 600 μl of the 
supernatant for each sample was then transferred into 5 mm (outer diameter) 
NMR tubes. 
1H NMR Spectroscopy. Spectra were obtained on a Bruker Avance600 
spectrometer (Bruker Biospin; Rheinstetten, Germany) at 600.13 MHz (ambient 
probe temperature 27°C). A standard 1-dimensional (1D) pulse sequence was 
used [recycle delay (RD)-90o-t1-90
o-tm-90
o-acquire free induction decay (FID)]. 
The water signal was suppressed by irradiation during the RD of 2 s, the mixing 
time (tm) of 150 ms. t1 was set to 3 μs and the 90
o pulse length was ~10 μs. For 
each sample, a total of 128 transients were accumulated into 32k data points 
using a spectral width of 20 ppm. Prior to Fourier transformation, all FIDs were 
multiplied by an exponential function equivalent to a line broadening of 0.3 Hz. 
The assignment of the peaks to specific metabolites was based on 2-dimensional 
(2D) 1H-1H correlation spectroscopy (COSY) and 1H-1H total correlation 
spectroscopy (TOCSY) NMR spectra, published literature,23, 24 and statistical 
total correlation spectroscopy (STOCSY).25 
 6 
Data Processing and Analysis. 1H NMR spectra of urine samples were 
manually phased and baseline corrected using XwinNMR 3.5 (Bruker Biospin; 
Rheinstetten, Germany). The 1H NMR spectra were referenced to the TSP 
resonance at  0.0. Spectra were digitized using a MATLAB (version 7, The 
Mathworks Inc.; Natwick, MA, USA) script developed in-house. The regions 
containing the water and urea resonances ( 4.5 – 6.5) were removed from each 
spectrum to eliminate baseline effects of imperfect water saturation. For each 
spectrum, a recursive peak alignment algorithm26 was applied to minimize 
spectral peak shifts due to residual pH differences within samples prior to 
normalization to the total area sum of the residual spectrum and subsequent 
pattern recognition analyses.  
Principal components analysis (PCA) was applied to the unit variance 
(UV)-scaled spectral data to reveal intrinsic autism-related patterns. Projection to 
latent structure discriminant analysis (PLS-DA) with UV-scaled spectral data was 
also carried out in order to improve classification of the different groups of 
individuals as well as to optimize the identification of changes in urinary 
metabolites that were unique to a particular group. Permutation testing (200 
permutations of the class parameters) was performed on the PLS-DA models to 
ensure statistical model validity. Inter-individual variation can confound data 
interpretation, particularly in multivariate data of high dimensionality. Therefore, 
orthogonal projection to latent structure discriminant analysis (O-PLS-DA)27 was 
also performed on UV-scaled spectral data to optimally model class differences 
and to systematically identify metabolites contributing to the differences between 
autistic, siblings and control groups. This is achieved by removing systematic 
variation in the profiles that does not relate to autism, thereby enhancing the 
interpretability of the models. Back scaling transformation of the O-PLS 
coefficients to the covariance matrix was also used to increase the interpretability 
of the model.28 Here, the colors projected onto the coefficient plot indicate the 
correlation of the intensities of the metabolites discriminating each class from the 
corresponding controls. Red indicates a high correlation and blue denotes no 
correlation with sample class. The direction and magnitude of the signals relate 
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to the covariation of the metabolites with the classes in the model and the model 
predictive performance (robustness) was evaluated using a 7-fold cross 
validation method as defined by the Q2 (goodness of prediction) parameter.28 In 
addition, the statistical significance and validity of the O-PLS-DA results were 
calculated using a permutation test (number of permutations = 10000).29, 30 The 
significance of each metabolite from the permutation test is interpreted using the 
covariance plot, where the colors projected onto the spectrum indicate the 
significance of the metabolites with blue indicating no significance difference at p 
> 0.05 confidence levels and red indicating high significance difference at p < 
0.0001; the direction and magnitude of the signals relate to the covariation of the 
metabolites with the classes in the model. 
Calculation of concentration ratios of selected urinary metabolites to 
creatinine. The relative mean concentrations of a range of urinary metabolites 
such as 4-cresol sulfate ( 2.35), creatine ( 3.93), glycine ( 3.56), hippurate ( 
7.84), N-methyl nicotinic acid (NMNA) ( 4.45), N-methyl nicotinamide (NMND) ( 
4.48), phenylacetylglutamine (PAG) ( 7.43), succinate ( 2.41) and taurine ( 
3.43) were calculated from the peak area of the designated NMR signals for the 
metabolites listed above using a MATLAB script developed in-house to partially 
overcome any concentration effects caused by different urine volumes. The 
ratios of the peak areas of these selected metabolites to that of creatinine  ( 
4.04) were then calculated and a non-parametric 2-tailed Mann-Whitney test was 
performed to calculate the significance level of class differences based on the 
ratios between groups. 
 
Results 
Urinary 1H NMR spectroscopic profiles of the cohort. Urinary 600 MHz 1H 
NMR median spectra of individuals from the 3 groups (Figure 1) contained peaks 
from a wide range of low-molecular-weight metabolites of diverse chemical 
classes (typically <1 kDa) from both mammalian and associated gut-microbial 
metabolism. The urinary NMR spectra were dominated by dietary and microbial-
derived methylamines (dimethylamine (DMA), trimethylamine N-oxide (TMAO)) 
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and aromatic substances such as hippurate, phenylacetylglutamine (PAG) and 4-
cresol sulfate (Figure 1). Additionally, mammalian metabolites such as citrate, 
succinate, creatinine, lactate, -hydroxyisobutyrate and amino acids (particularly 
alanine, glutamine and glycine) were also apparent. Visually, allowing for the 
inter-individual variability, the urinary spectra were very similar, but the autistic 
individuals showed subtle differences in urinary succinate, N-methyl nicotinic acid 
(NMNA) and N-methyl nicotinamide (NMND) compared to the controls, as 
evidenced from the median spectra shown in Figure 1.  
Multivariate statistical analysis of the NMR spectral data.  To further explore 
the metabolic differences between the three groups of participants, multivariate 
statistical analyses were employed on the full resolution NMR data set consisting 
of 34 controls, 28 siblings and 39 autistic urine samples to extract useful 
metabolic information. PCA was carried out on UV-scaled data to identify any 
inherent differences within the dataset. The resulting scores plot of PC1 versus 
PC2 (Figure 2A) showed no clear differences between the three groups, nor did 
examination of all pairs of lower PCs up to 3 PCs  provide any discrimination 
indicating that the major source of variation in the data was not related to autism, 
but was rather dominated by inter-person variability. However, by utilizing group 
information in PLS-DA analysis, systematic differences could be observed 
between the three groups (Q2: 15%; R2 (goodness of fit): 65.7%). The 
corresponding cross-validated PLS-DA scores plot (Figure 2B) showed clear 
separation between autistic individuals and the controls and partial separation 
between siblings and the controls. PLS-DA pair-wise comparison between 
controls and siblings (Figure 2C; Q2: 31.4%, R2: 86%), and between controls and 
autistics (Figure 2D; Q2: 33.5%, R2: 72%) suggested a robust metabolic 
difference between the classes in each pair-wise comparison (Figure 2C and D 
respectively) on the first component. 
To minimize any effects of non-relevant metabolite variability, pair-wise O-
PLS-DA analyses were carried out on the UV-scaled NMR data set to identify 
urinary metabolites contributing to the differences between groups. Systematic 
comparisons of the autistics and normal control groups using O-PLS-DA 
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generated a model with a Q2 of 15% and R2 of 27.5%. The corresponding 
coefficients plot (Figure 3) indicated differences in the urinary metabolic profile 
between the two groups with the autistics showing relatively higher levels of 
urinary acetate, DMA, N-acetyl glycoprotein fragments (NAG), succinate, taurine, 
NMNA, NMND and N-methyl-2-pyridone-5-carboxamide (2PY), whilst the healthy 
controls showing higher levels of urinary glutamate, hippurate, PAG, and 4-cresol 
sulfate. Comparison between siblings and the controls, and between siblings and 
autistics, using O-PLS-DA, showed no differences in the urinary metabolic profile 
(data not shown) and the models generated were very weak (negative Q2). 
Permutation tests were carried out on the pair-wise area-normalized NMR data to 
statistically validate the results obtained from the O-PLS-DA analyses. Pair-wise 
comparison between the controls and autistic individuals showed statistical 
significance at a p < 0.0001 significance level (Figure 4) on all metabolites 
identified to be contributing to the differences between controls and autistics in 
the O-PLS-DA analyses (Figure 3). However, permutation tests carried out on 
the controls and siblings failed to find statistical significance in the urinary 
metabolites (data not shown), which is reflective of the weak Q2 and R2 values 
generated from the O-PLS-DA model. 
Ratios of selected urinary metabolite concentrations against creatinine. 
The areas of selected NMR peaks from a range of urinary metabolites 
determined to be significantly different between groups via multivariate statistical 
modeling, such as creatine, creatinine, glycine, hippurate, NMNA, NMND, PAG, 
4-cresol sulfate, succinate and taurine were quantitated and ratios obtained 
relative to that of the methylene peak of creatinine. The significance of the ratio 
differences between all three sample classes were then determined as described 
in the Methods section since the data were shown not to be normally distributed 
(Figure 5). The results showed statistical significance at a 5% significance level 
for both NMNA and NMND between autistic and control individuals. NMNA, 
NMND and succinate were found to be significant between siblings and autistic 
individuals in the pair-wise comparison (Figure 5). Although we observed a trend 
towards decreased excretion of hippurate, 4-cresol sulfate and 
 10 
phenylacetylglutamine in the autistic group due to a high degree of variability, 
possibly reflecting multiple sub-phenotype for the autism group, the t-test results 
for these metabolites were not statistically significant 
 
Discussion 
The results of this study have shown significant differences in the metabolic 
composition of urine between children with autism and unrelated non autistic 
controls. Statistical analysis of the urinary NMR data using O-PLS-DA 
coefficients, permutation testing or univariate t-test on the ratios of selected 
metabolites to creatinine, indicated that children with autism have lower levels of 
urinary hippurate and PAG, and higher levels of urinary DMA. More importantly, 
this study showed that children with autism demonstrate systematic metabolic 
differences as compared to normal controls. Pattern recognition analyses 
indicated that the main metabolic changes were in concentrations of mammalian-
microbial co-metabolites such as DMA, hippurate, PAG, and 4-cresol sulfate and 
in nicotinic acid metabolism as evidenced by changes in the levels of 2PY, 
NMNA and NMND. Additionally amino acids such as taurine and glutamate, NAG 
and succinate were consistently altered in the ASD group. Additionally, from 
univariate t-tests on the ratios of selected metabolites to creatinine analysis, 
NMNA, NMND and succinate were found to be significantly different between the 
siblings and the controls, which indicated that the siblings were also different 
from the controls although multivariate analysis did not reflect this changes. 
Gut microbial/host co-metabolite differences. Changes in the levels of urinary 
aromatic compounds such as 4-cresol sulfate, hippurate and PAG suggested the 
involvement of gut microflora in autism, since their precursors, benzoic acid, and 
phenylacetic acid respectively, are produced by bacterial metabolism in the 
intestine.31-34 Hippurate is predominantly formed by hepatic glycine conjugation 
of dietary and gut microbial-derived benzoate, which is derived from plant 
phenolics.33 Here, the decreased urinary levels of hippurate is suggestive of 
reduced benzoic acid synthesis. Protein-derived aromatic amino acids such as 
phenylalanine and tyrosine are also catabolized by host gut microbiota to form 
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PAG and 4-cresol sulfate.31, 34 Gut microbiota have been shown to facilitate host 
energy recovery from dietary sources by providing refined control mechanisms 
on energy recovery through catabolism of otherwise poorly digestible nutrients 
e.g. resistant starch.35 Changes in the concentrations of urinary hippurate and 
PAG have been previously linked to the effects of xenobiotics on the intestinal 
microbial metabolism.36 Depletion of hippurate and PAG has been reported after 
ingestion of antibiotics such as vancomycin12 and gentamicin.37 In addition, 
gastrointestinal microbial analysis of fecal samples from children with late-onset 
autism has shown that autistic individuals have higher incidence of the 
Clostridium histolyticum group of bacteria, as well as increased diversity of 
clostridial species11, 13, and individuals with autism have been shown to have 
abnormalities in hippurate excretion.38 Abnormalities of the gut microbiota 
including the Clostridium sp. a group of bacteria with a wide range of species 
variation in host hostility have also been noted in autistic children.11 Many 
species of clostridia can produce powerful neurotoxins, and these have been 
implicated in ASD with certain clostridial species being found to be specific to 
autistic individuals (and not present in non autistic children).13 The fecal 
mircobiota of ASD individuals have been found to contain higher numbers of the 
Clostridium histolyticum group of bacteria in comparison with to healthy children. 
Their non-autistic siblings were found to have intermediate levels of the same 
group of bacteria indicating that the importance of gastrointestinal microbiota 
composition in ASD may be influential in the development of the condition.11 
However, further metagenomic studies on the fecal samples of these children will 
be required to confirm the exact role of the gut microbiota species variation. The 
changes in urinary mammalian-microbial co-metabolites, observed in the current 
study, highlight the potential involvement of gut microbiota in autism and warrant 
further investigation of the effect of gut microbe metabolites on early brain 
function development. 
 
Endogenous biochemical differences in autism: In the present study, urinary 
amino acids glutamate and taurine, were found to be perturbed in autistic 
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individuals as compared to the controls in the pattern recognition analyses. 
Several studies have shown that children with ASD often suffer from 
dysregulated amino acid metabolism.39, 40 In addition, Rolf et al. reported that 
platelet serotonin was significantly increased and amino acids aspartate, 
glutamine, glutamate and -aminobutyrate were significantly decreased in autistic 
individuals compared to the controls41 and Arnold et al. found significantly lower 
levels of glutamine in 12 autistic children compared to age-matched controls.42 
The increase in urinary NAG in the autistic group could indicate the involvement 
of autoimmunity in autism since increased excretion of NAGs in serum and urine 
have been associated with inflammatory conditions43, 44 and autoimmunity has 
been implicated in autistic children.45 The changes in urinary succinate in the 
current study suggested a change in energy metabolism since succinate plays a 
biochemical role in the citric acid cycle. However, it is likely that the change 
observed in succinate is related to the perturbation in amino acid metabolism as 
observed in the current study. 
2PY, NMNA and NMND, metabolites of nicotinic acid metabolism, were 
found to be increased in individuals with autism, and were the group of 
metabolites with the greatest discriminating power between autistics and age-
matched controls by the univariate analyses. The differences observed in these 
metabolite concentrations cannot be explained simply by intake of exogenous 
compounds since the samples used in the data analysis were pre-selected from 
individuals, who were reported not to have taken vitamin supplements. These 
metabolites are end-products of nicotinamide metabolism, which is derived from 
tryptophan. Nicotinamide is involved in the tryptophan-NAD pathway that 
supplies pyridine nucleotides to the liver. Nicotinamide is metabolized to NMND 
via nicotinamide N-methyltransferase and subsequently to 2PY and N-methyl-4-
pyridone-3-carboxamide (4PY) via the action of aldehyde oxidase.46, 47 Nicotinic 
acid metabolism and high excretion of NMND has been implicated in Parkinson’s 
disease.48-50 NMND has been shown to have N-methylated pyridines-like 
dopaminergic toxicity.51 NMND has also been demonstrated to destroy cerebral 
complex 1 subunits52 and complex 1 deficiency plays a role in the pathogenesis 
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of Parkinson’s disease.53-55 The changes in urinary 2PY, NMNA and NMND 
observed in the current study suggested possible perturbation of tryptophan-
nicotinic acid metabolism in autistic individuals.  
Sleep disorders are common in autism and melatonin supplementation is 
used for treatment.56 Perturbation in tryptophan-serotonin-melatonin pathways 
has also been implicated in autism.57, 58 Tryptophan acts as a biochemical 
precursor for both melatonin and nicotinic acid. The increases in the metabolites 
of nicotinic acid metabolism would indicate an increase in tryptophan metabolism 
towards the formation of nicotinic acid. This can be due to reduced enzyme 
activity converting tryptophan to serotonin and subsequently to melatonin. The 
conversion of tryptophan to melatonin involves two enzymes, tryptophan 
hydroxylase and acetylserotonin methyltransferase (ASMT).59 Autistic individuals 
have been shown to have reduced ASMT enzyme activity.59 Therefore, a 
decrease in conversion of tryptophan to melatonin could consequently lead to an 
increase in nicotinic acid synthesis as reflected in this study. Melatonin was not 
observed in the current study because of its expected low urinary concentration, 
below the limit of NMR detection.  
Autistic children are known to suffer from a decreased capacity for 
methylation and vulnerability to oxidative stress.60, 61 James et al (2004) 
measured plasma concentrations of methionine, S-adenosylmethione (SAM), S-
adenosylhomocysteine (SAH) and other sulfur-containing metabolites and found 
that autistic children have significantly lower plasma concentration of methionine, 
SAM (an important methyl donor), homocysteine and total glutathione relative to 
control children.60 An increased demand for methylation of nicotinic acid to its N-
methylated acid and amide as observed in our study would exert further stress 
on what is already a compromised methylation capacity in autistic children 
leading to increased susceptibility to oxidative stress.  
The increase in urinary taurine in the autistics could be indicative of 
alteration in cysteine metabolism in autistic individuals. Taurine levels were found 
to be significantly increased in autistic children as evidenced by the results of the 
permutation test. However, taurine concentrations were hypervariable in the 
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autistic group, which did not detect any difference between groups based on t-
test analysis. Nevertheless, this hypervariability is in itself interesting and may 
indicate the presence of more than one phenotype associated with autism. As 
noted above, oxidative stress has been suggested to contribute to the 
development of autism.60-63 Taurine plays an important role in cellular protection 
against free radical and oxidative stress. Children with autism have been shown 
to have low plasma levels of inorganic sulfate and sulfur oxidation deficiencies.14 
In a follow-up study, Waring and Klovrza showed that urinary excretion of sulfate, 
sulfite and thiosulfate were increased in autistic children further supporting 
perturbation in sulfur metabolism.14 They postulated that an increase in urinary 
sulfur indicated dysfunction in specific sulfate transporters, NaSi and SAT-1.14 
These transporters are involved in transporting sulfate across the apical and 
basolateral membranes of the renal tubule cells thus playing an important role in 
maintaining body supplies of sulfur and sulfate. The increase in urinary taurine 
observed in this study is further evidence that these children may suffer from a 
defect in sulfate transporters and abnormal sulfur metabolism. Indeed it is known 
that autistic children have an inability to sulfate phenolic compounds and drugs 
such as acetaminophen,14 which also implicates a fundamental problem with 
sulfur dependent detoxification reactions. Reduced capacity to sulfate 
acetaminophen has also recently been noted in normal humans with high 
predose 4-cresol levels,64 which is a compound produced by selected clostridia, 
which are themselves abnormal in autistic children.13 We have recently shown 
that even in normal individuals high levels of gut microbially produced 4-cresol 
can compromize sulfation of acetaminophen at therapeutic doses, and further 
that N-acetyl cysteinyl and cysteinyl adducts of acetaminophen are lower in 
urines of people with high levels of pre-dose 4-cresol sulfate.64 This suggests a 
generalized depletion of sulfur metabolism (including the glutathione pathway) 
and a consequent inability to detoxify reactive intermediates and this may have 
long term significance in autistic patients. The possible connections between 
abnormal microbial metabolic activity and abnormal sulfur metabolism in the host 
and whether these have any etiologic or developmental significance are 
 15 
intriguing possibilities but require further investigation in longitudinal 
developmental studies. 
 
Conclusions 
This work has characterized a series of urinary metabolic changes that are 
associated with autism. Specifically, the metabolic profiling approach also 
indicated changes in gut microbiota metabolism, amino acid metabolism and 
nicotinic acid metabolism in autistic children. The excretion patterns of a panel of 
urinary metabolites viz hippurate, NMNA, NMND and taurine were abnormal and 
these now need further validation as potential biomarkers for autism. Also, 
whether the metabolic differences are related to the causes of the condition or 
are a consequence of the progression of the disease, remains to be determined 
in larger scale longitudinal studies.  It should be noted however that biomarkers 
of any established disease condition are not necessarily the same as those 
occurring during the disease etiology and that mechanistic understanding would 
be further enhanced by studying larger groups of early onset patients much 
closer to the time of diagnosis. Nevertheless, further investigation of the 
metabolic pathways that we find to be perturbed in the present study could 
provide new clues to the etiology of autism and give rise to novel criteria for 
therapeutic interventions. 
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Figure legends 
 
Figure 1. (A) Median 600 MHz 1H NMR spectra of urine from the groups of 
control, sibling and autistic individuals. The spectral region of nicotinic acid 
derivatives ( 8.6-9.5) is shown in the inset. 
Key: 2PY*, tentatively assigned as N-methyl-2-pyridone-5-carboxamide; DMA, 
dimethylamine; DMG, dimethylglycine; NMNA, N-methyl nicotinic acid; NMND, N-
methyl nicotinamide; TMA, trimethylamine; TMAO, trimethylamine N-oxide; PAG, 
phenylacetylglutamine; 4CS, 4-cresol sulfate;  
Figure 2. (A) PCA scores plot of the first 2 components from the normalized UV-
scaled NMR data and (B) the corresponding PLS-DA cross-validated scores plot 
for all three group. PLS-DA cross-validated scores plot of pairwise comparison 
between (C) controls versus siblings and (D) controls versus autistics. 
Figure 3. O-PLS-DA coefficients plot showing differences in urinary profiles 
between controls and autistics. 
Figure 4. Covariance plot showing the significance of the urinary profiles 
calculated using the permutation test between control and autistics. 
Figure 5. The ratio of selected urinary metabolites to that of urinary creatinine 
across the 3 groups. 
Key: *, ***, indicates a significant difference at p < 0.05, 0.001 confidence levels 
respectively. 
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Synopsis 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Autism is an early-onset developmental disorder with complex 
neurodevelopmental and socio-psychological problems associated with 
metabolic abnormalities. A suite of metabolic changes that are associated with 
autism were characterized using NMR-based metabonomic and show systematic 
differences in the urinary composition of autistic children with respect to their 
non-symptomatic siblings and age matched controls. Several metabolic 
pathways were shown to be affected by autism in this study, which opens new 
directions for validation of potential biomarkers. 
